Get help from the best in academic writing.

Customer Experience Strategy of Samsung Mobile Phones Report

Customer Experience Strategy of Samsung Mobile Phones Report.

You are required to write a 2,500 word report on the customer experience (CX) strategy of Samsungfor their mobile phone product lines. You should base your report on the analysis of their CX strategyin one specific country in which they operate, which you must identify in the introduction to yourreport.You should write your report for the Board of Directors. Within the business report, referenceshould be made to relevant CX concepts, literature and application as appropriate. Only use tables toanswer the requirements where it is suggested to do so.You need to address the following tasks:1. The importance of customer experience : you should define and explain what ismeant by and included under the term customer experience. Appraise the importance of CXin the case of Samsung mobile phones. 2. Customer journey : explain what a customer journey is and why it is important toCS strategy, including the purpose of each of the main elements: journey stage, activities,feelings and needs. 3. Persona creation : explain what a consumer persona is and evaluate its role indeveloping effective CS strategy. In application to Samsung identify and justify three key,different consumer personas. Select one of the three consumer personas and for thispersona provide the following elements in a visual format (table or graphic):a. Demographics and storyb. Profilec. Motivations for using a Samsung mobiled. Goals for using a Samsunge. Painpoints a Samsung mobile solves4. Mapping the customer journey (8 marks) In relation to your most significant consumerpersona identified in task 3, using a table, map their customer journey. This should includethe following:a. Stages of journeyb. Activitiesc. Feelings and needsd. Potential opportunities for improvement(Suggested word count: n/a since table format.)5. Omnichannel marketing : explain what is meant by omnichannel marketing andthe role of interaction and customisation in omnichannel marketing. Identify for Samsungmobiles the different marketing channels used and analyse how effective Samsung is inachieving a seamless customer journey. 6. CX performance metrics: identify 5 CX performance metrics and evaluate theirimportance. This can be presented in table format. Propose and explain which 2 are themost important in the case of Samsung mobiles. 7. CX processes in different industries : briefly compare the CX processes inSamsung to that of another company of your own choice in another industry and discuss andexplain 5 key success factors common to both. Appraise the role of the CX governance indriving successful CX strategy. 8. Conclusion (5 marks): having completed your report provide a conclusion on how effectiveSamsung’s CX strategy is, using evidence from the previous seven tasks to support yourreasoning.9. Presentation : present your report in a structured and professional manner usingHarvard referencing guidelines.
Customer Experience Strategy of Samsung Mobile Phones Report

Cetuximab Antibody Production. Cancer has been studied widely for many decades and is a major part of ongoing research worldwide. During the research a new generation of so-called targeted therapies have been produced to target specific molecular processes that promote cancerous tumour growths. The research lead to development of the drug called Cetuximab which is used to treat head and neck cancers and colon and rectum cancers including large bowel. It is produced under the brand name of Erbitux which is produced by Merck Serono company which is located in Dublin 24 in Ireland. Cetuximab is widely produced in US by several pharmaceutical companies such as Imclone, Bristol Myers Squibb and in UK as well. The treatment with Erbitux is very expensive and the reason for that is because it is a chimeric monoclonal IgG1 antibody which is produced in a mammalian cell line by recombinant DNA technology which requires cost expensive labour and ingredients. (http://www.medicines.ie/medicine/12082/SPC/Erbitux 5mg ml solution for infusion/ 2010) One of the widely studied areas is molecular targets such as epidermal growth factor receptor (EGFR) which lead to development of Cetuximab which works on these molecular targets. Cetuximab works by inhibiting activation of epidermal growth factor receptor (EGFR). Cetuximab was approved by (FDA) Food and Drugs Administration for the use in the treatment of head and neck squamous cell carcinoma (HNSCC) using the combination of radiotherapy and for metastatic colorectal cancer (mCRC) as single drug or in combination with chemotherapy. (Bruno Vincenzi, Gaia Schiavon, Marianna Silletta, Daniele Santini, Giuseppe Tonini, 2008) Cetuximab is a recombinant chimeric human murine immunoglobulin G1 antibody that binds to the extra-cellular domain of epidermal growth factor receptor with a higher affinity than either endogenous ligand. This binding inhibits receptor phosphorylation and activation and it leads to receptor internalization and degradation. Several studies have shown that cetuximab is able to inhibit growth of epidermal growth factor receptor (EGFR)-expressing tumour cells in vitro. Moreover, treatment with cetuximab results in a marked inhibition of tumour growth in nude mice bearing xenografts of human cancer cell lines. These results are linked to cetuximab biological effects as inhibition of cell cycle, tumour progression, neo-angiogenesis, invasion and metastatization, as well as increase and activation of pro-apoptotic molecules. Additionally, cetuximab potentiates, in combination, the effects of chemotherapy and radiation therapy in eradicating well-established tumours in nude mice and it may even reverse the resistance to some cytotoxic agents in these xenografts. Moreover, numerous clinical trials demonstrated cetuximab efficacy in different tumour types. It has been approved by Food and Drugs Administration in the treatment of metastatic colorectal cancer as single agent or in combination with chemotherapy, in locally and regionally. (Bruno Vincenzi , Gaia Schiavon, Marianna Silletta, Daniele Santini, Giuseppe Tonini 2008) Cetuximab is a chimeric human murine derivative IgG1 monoclonal antibody (mAb) that binds extra-cellular domain of the EGFR. This binding inhibits activation of receptor tyrosine kinase and the associated downstream signalling that includes the mitogen-activated protein kinase (MAPK), phosphoinositide 3-kinase (PI3K)/Akt and the Janus kinases (Jak) signal transducers and activator of transcription pathways. Furthermore cetuximab induces antibody-mediated receptor dimerization, internalization and degradation leading to receptor down-regulation. In addition, it can determine antibody-dependent cellular cytotoxicity (ADCC) that could contribute to its antitumoural effect. EGFR is expressed on normal and malignant epithelial cells and it plays an important role in tumour biology. In fact, it promotes proliferation, metastatization, angiogenesis and inhibition of apoptosis. (Bruno Vincenzi, Gaia Schiavon, Marianna Silletta, Daniele Santini, Giuseppe Tonini, 2008 p. 94) The most common EGFR alteration in tumour cells is its over-expression that may lead to ligand-independent receptor dimerization. EGFR is frequently over-expressed in human tumours including breast cancer, lung cancer, glioblastoma, bladder carcinoma, head and neck cancer, ovarian carcinoma, colorectal cancer and prostate cancer. Overexpression of EGFR determines the rate of disease progression and aggresivness of cancer. The rate of expression of EGFR can give an overall picture on diagnosis and prognosis of cancer. Table 1 Rate expression of EGFR in different tumour types Tumour type Rate of EGFR expression Head and neck 90‚100% Breast Up to 91% Renal Up to 90% Cervical Up to 85% NSCLC Up to 80% Colon Up to 89% Ovarian Up to 77% Prostate Up to 47% Glioma Up to 63% Pancreas Up to 95% Bladder Up to 72% EGFR: epidermal growth factor receptor, NSCLC: non-small cell lung cancer. (Bruno Vincenzi , Gaia Schiavon, Marianna Silletta, Daniele Santini, Giuseppe Tonini, 2008 p. 95) The mechanisms through which cetuximab expresses its antitumour activity are numerous and not completely understood yet. Different studies demonstrated that cetuximab mediates cell cycle arrest in various tumour cell lines, leading in some cases to apoptosis (programmed cell death). Numerous studies has proven that cetuximab decreases tumour cell production of angiogenic growth factors such as vascular endothelial growth factor (VEGF), bFGF and interleukin-8 (IL-8). The decrease in angiogenic growth factors, in turn, correlates with a significant decrease in microvessel density and an increase in apoptotic endothelial cells in human tumour xenografts. Angiogenesis is a complex process through which new blood vessels arise from existing vasculature. It is tightly regulated by balance between pro-angiogenic and antiangiogenic factors and it involves autocrine and paracrine signalling. (Bruno Vincenzi, Gaia Schiavon, Marianna Silletta, Daniele Santini, Giuseppe Tonini, 2008 p. 97) Both in vitro and in vivo experiments have proven that cetuximab inhibits the invasive and metastatic ability of different tumour types. Tumour invasion is a complex process that needs active interactions between tumour cell, the extra-cellular membrane (ECM) and other stromal elements Different coordinated events are required for cell invasion: firstly, changes in cell‚ cell and cell‚ matrix adhesion, secondly, degradation of ECM, and finally, cell migration, cytoskeletal rearrangement and acquisition of enhanced proteolytic potential. (Maria Luisa Veronese, Peter J. O’Dwyer, 2004) Cetuximab has been shown to inhibit the expression and activity of several MMPs (Matrix Metalloproteinase enzymes related to tissue healing/remodeling and cancer cell metastasis) including the gelatinase MMP-9. Several studies correlated this antibody-mediated reduction in MMP production with both a significant reduction in in vitro tumour-cell invasion and the inhibition of tumour growth and metastasis in nude mice. Compared with its inhibitory properties, cetuximab immunologic mechanisms have not been extensively studied. Cetuximab may be trigger an ADCC reaction, leading to an indirect antitumour activity by the recruitment of cytotoxic host effector cells such as monocytes and natural-killer cells. Cetuximab ADCC (antibody-dependent cellular cytotoxicity) activity has been described against several tumour cell lines expressing wild-type or mutant EGFR. (Bruno Vincenzi , Gaia Schiavon, Marianna Silletta, Daniele Santini, Giuseppe Tonini 2008 p. 98) Cetuximab, the medicinal ingredient of Erbitux, is a recombinant, human/mouse chimeric monoclonal antibody that binds specifically and with high affinity to the extracellular domain of the human epidermal growth factor receptor (EGFR). Cetuximab functions as a competitive antagonist that inhibits the binding of ligands to EGFR which results in the inhibition of growth and survival of tumour cells that express EGFR. Cetuximab is produced by recombinant DNA technology in a mouse myeloma derived cell line. The manufacture of cetuximab is based on a master and working cell bank system, where the master and working cell banks have been thoroughly characterized and tested for adventitious contaminants and endogenous viruses in accordance with the ICH guidelines. Results of these tests confirmed cell line identity and absence of adventitious agents/viral contaminants. Genetic characterization (restriction endonuclease mapping and copy number analysis) also demonstrated genetic stability of the master cell bank ranging from storage to production at the limit of in vitro cell age. The manufacture of cetuximab comprises a series of steps which include cell culture, harvest, and purification. The purification is performed via a combination of chromatographic and viral inactivation/removal steps. The consistency of the manufacturing process is ensured through defined production procedures, critical quality tests, in-process limits and cetuximab certificate of analysis specifications. Microbial control is maintained throughout the manufacturing process by testing for bioburden as well as for bacterial endotoxins. In-process controls performed during manufacture were reviewed and are considered acceptable. The specifications for the raw materials used in manufacturing the drug substance are also considered satisfactory. The Erbitux manufacturing process consists of adjusting cetuximab formulated bulk concentration and filling into vials using proper aseptic process techniques, and conventional pharmaceutical equipment and facilities. Erbitux is manufactured within the lab which obeys GMP (Good Manufacturing Practise). One-hundred percent of the patients in the pivotal trial experienced an adverse event (AE). Eighty percent of these were grade 3 or 4 in nature. The most commonly reported AEs in order of frequency were asthenia, diarrhea, nausea, abdominal pain and acne. Based on the data from this trial, the AE profile of the combination of irinotecan and cetuximab is the aggregate of the AE profile of each individual agent. There was no evidence that the addition of either agent exacerbated the AE profile of the other agent, nor was there any evidence of frequently occurring new AEs. The most common AEs associated with irinotecan were less frequent than in other trials with irinotecan in CRC. Similar results were observed in the non-pivotal studies. (http://www.hc-sc.gc.ca/dhp-ps/prodpharma/sbd-smd/phase1-decision/drug-med/sbd_smd_2007_erbitux_088225-eng.php 2007) The treatment with Erbitux is very expensive and the reason for that is because it is a chimeric monoclonal IgG1 antibody which is produced in a mammalian cell line by recombinant DNA technology which requires cost expensive labour and ingredients. Erbitux is available in injectable form only and contains 5mg/ml solution for infusion. Erbitux is a colourless solution. Cetuximab is available for injections in different vial sizes: vial of 10 ml contains 50 mg cetuximab vial of 20 ml contains 100 mg cetuximab vial of 50 ml contains 250 mg cetuximab vial of 100 ml contains 500 mg cetuximab Cetuximab is used for the treatment on patients with epidermal growth factor receptor (EGFR)-expressing, KRAS wild-type metastatic colorectal cancer in combination with chemotherapy. It can also be used for the the treatment of patients with quamous cell cancer of the head and neck in combination with platinum-based chemotherapy for recurrent metastatic disease. Patients who receive treatment first time must receive treatment with corticosteroid and antihistamines in order to avoid allergic reaction to the drug and body attacking the drug. It is also recommended to receive treatment with corticosteroids and antihistamines for all subsequent infusions. For all types of treatments Erbitux is administered once per week. The starting dose is 400 mg of cetuximab per m2 body surface area. All subsequent weekly doses are 250 mg cetuximab per m2 each. Cetuximab can be used in patients with colorectal cancer as a single drug or in combination with chemotherapy. For patients with squamous cell cancer of neck and head it is used together with radiation therapy. Allergic skin reactions are very common with Cetuximab patients which occur in more than 80% of patients, the reason for that is because Cetuximab is a chimeric monoclonal antibody drug. The majority of allergic skin reactions will develop within the first 3 weeks of treatment. These include dry skin, skin rash, eczema, nail disorders, in some severe cases skin necrosis. These skin problems generally resolve once the treatment is ceased. Sometimes Cetuximab can cause skin lesions and patients with sensitive skin may develop superinfections like MRSA, or in other cases cellulites, sepsis, or scalded skin. (http://www.medicines.ie/medicine/12082/SPC/Erbitux 5mg ml solution for infusion/ 2010) Cetuximab works in many different ways : it inhibits cell cycle progression metastatization and invasion, angiogenesis, increase and activation of pro-apoptotic molecules. When cetuximab is used in combination with chemotherapy and radiotherapy its effects are synergic. Effectivenes is much higher if when used in combination rather than separately. Cetuximab is relatively new drug and it is not fully understood its working mechanisms and new types of drugs like cetuximab promise effective treatment against cancer. Cetuximab Antibody Production

University of California Irvine Mexican American War Research Paper

University of California Irvine Mexican American War Research Paper.

Identifications: La MalincheMexican American WarTreaty of Guadalupe HidalgoRepatriationThe responses must be in short essay format and include the following:WhoWhatWhenWhereWhy (significance) Make sure you think critically of the significance. For example, why is the Treaty of Guadalupe Hidalgo important? What were the ramification of the Treaty?You can only use the readings in the attachment as resources in your responses. Length of a response should be approximately half a typed page, single spaced.In your response please use MLA citations. You must cite at least from one article from your assigned readings. Last name of author and page numbers inside parenthesis suffices. For example, (Gutiérrez, 34).No Works Cited Page/Bibliography needed. Only in-text citation is required.
University of California Irvine Mexican American War Research Paper

Unit 7 Risk Management and Employee Monitoring Discussion Response

assignment writer Unit 7 Risk Management and Employee Monitoring Discussion Response.

References with the articles attached:
Textbook(s)
Fraser, J., & Simkins, B. J. (2010). Enterprise risk management. Wiley.
Henry, J. C., Brown, D. M., Sullivan, L. L., & Thompson, C. L. (2020). The Illusion of Employee Privacy. Journal of Business & Accounting, 13(1), 114–123.
Austermuehle, E. (2018). Monitoring Employees Through GPS Technology: What Is Legal and What Are Best Practices? Employee Relations Law Journal, 44(1), 10–14.
Shah, N. R., & Jha, S. K. (2018). Exploring Organisational Understanding of Foundational Pillars of Social Media: A Qualitative Content Analysis of Social Media Policies of Technology Companies. Journal of Management Research (09725814), 18(4), 226–245.
Discussion Question below:
What are your thoughts on employee privacy? Should there be organizational limits on employee monitoring?  What do you think should be included in social media policies?
Unit 7 Risk Management and Employee Monitoring Discussion Response

Sports Science Principles in Melbourne Football Club Report

Executive Summary The athlete team under analysis in this paper is the Melbourne Football Club (Demons). Its main issue is poor on-field performance, caused by mediocre coaching, waning motivation, and low fitness. The three sports science disciplines that are useful for Melbourne Football Club are coaching, athlete career training and education, and sports psychology. Some of the research findings on effective coaching will be applied to the Demons to enhance performance. Research on athlete career and training will be essential in improving the team members’ fitness levels, talent recruitment, and talent development strategies. Studies in sports psychology will assist in identifying and tackling negative external motivation among the players. The intervention will involve a three-pronged approach designed to tackle most of the causes of poor on-field performance in Melbourne Football Club. First, it will consist of an intensive strength and conditioning program. Secondly, it will entail the hiring of new coaching personnel. Finally, it will involve the reorganization and hiring of players. A new coach, assistant coach, and performance manager will be in charge of the intensive strength and conditioning program. The plan will cost USD1.98 million to come from the club’s key corporate partners. This intervention will likely lead to a highly enthusiastic and motivated team. The plan will also improve their form and fitness levels. Additionally, it will prevent the occurrences of fatigue. Most importantly, the intervention will lead to improved performance of the Melbourne Football Club. Background The athlete team under analysis in this paper is the Melbourne Football Club; it is also known as The Demons. This team of Australian Football League players has been performing abysmally over the past decade. It was one of the oldest teams in the sport with a long impressive performance in the past. However, now the team is losing to teams like Port that was perceived as non-threatening. Furthermore, even the nature of their losses is quite demoralizing. In a round-two match this season (April 2013), the team lost by 148 points. Their defeaters – Essendon – had a final score of 184 while the Demons could only garner a measly 36 points. The club has recorded such disappointing performances over the past few years, with only a few wins to pacify their supporters. Melbourne Football Club’s main issue is poor on-field performance (Mitchell, 2013). Experts attribute this poor performance to several reasons. First, they believe that the current coach is a poor fit for the team (Cummings, 2013). Coach Mark Neeld allowed television reporters into the team’s changing room before a match this season. Many viewers and reporters criticized him for his bland and uninspiring speech to a team that urgently needed some motivation. Others believe that the coach’s list management techniques were wanting; they claim that individuals who could perform better as forwards were defenders and vice versa (Cummings, 2013). Neeld seems to lack proper game strategies because some of his team members have not mastered the basics. His team does not tackle, pass, and defend the ball in the right manner. Furthermore, the Demons have been using the same game plan for the past two years. Their opponents know about it and have defeated them using this knowledge. Some say that the coach is simply not pushing the players hard enough (Cutain, 2013). There is a disparity between what he intends for them and how the team perceives his message. Even his recruitment strategies have been put under question. Analysts blame him for hiring recycled and old players from other teams (Cummings, 2013). They also believe that he did not secure the right individuals to come into the team as first-timers. Several specialists and fans have also blamed the team leadership. The club’s immediate former iCEO Cameron Schwab barely removed the club out of debt. His group was responsible for the recruitment and selection of coaches. Therefore, his poor insight affected the outcomes of the players. Additionally, senior management often approves player choices and affects the financial viability of the club. If management lacks control over these issues, then players will be demoralized and could walk away. The club has been making poor choices when appointing senior managers. Get your 100% original paper on any topic done in as little as 3 hours Learn More In this issue of poor on-field performance, the players are also not free from blame. Some of them lack the sense of urgency needed to make it to the Australian Football League. Additionally, others are not enthusiastic about their games and appear to be there only out of obligation. Some of them have mismanaged their careers and failed to develop as required. Jack Watts is one such example; he was promising as a junior but did not apply consistent effort. Newer players appear to lack the confidence needed to confront giants of the sport. The players appear to be unfit; a number of them get tired minutes before the game is over, and simply give up. They also lack clear leadership in the field as competitors have poached some of their best players. Leadership in the field does not occur by default; older players need to demonstrate to the younger ones exactly what needs to take place. This means that the players should come from free agencies. On the part of the players, poor talent development, lack of motivation, and low fitness levels account for these dreadful results. The problem has occurred recurrently over the past three decades. It started due to a financial crisis in the company, loss of key players, and inappropriate response from the club administration. Several other complications have piled up since its key crises. These issues must be tackled explicitly or they could spiral out of control. Failure to respond to the poor on-field performance could lead to a decline in support from key sponsors. This could spell doom for all the sports personnel who depend on the Club for support. It could also be wasteful to the athletes who dedicated most of their sporting life to the team. Perhaps the fans will be the most disenchanted group if the Demons fail to turn their performance around. Many enthusiasts have supported the team since their childhood, so it would be depressing to witness the fall of a club that they loved for so long. Melbourne Football Club owes its stakeholders the responsibility of staying on form and replicating the glorious days of success. Its historical significance to Australian Rules Football makes it necessary for the team to succeed. Explanation of sports science disciplines The three sports science disciplines that are useful for Melbourne are coaching athlete career training and education, and sports psychology. Coaching encompasses aspects of team preparation that depend on a trainer. The coach is responsible for selecting athletes, training, motivating, and preparing a game strategy. Athlete career training and education encompass aspects that deal with talent development, career progression as well as training in sports. Sports psychology is a vast discipline that focuses on discovering how psychological attributes affect physical performance. It also uncovers the effect of physical exercise on psychological development. Some of the key advancements in the field of coaching include the association between coaching leadership style and team performance, characteristics of attributes that make a coach effective, and motivational techniques that coaches apply to elicit impressive performance from their teams. Scholars like Turman (2003)

FUE WK 2 Improving Sleep and Managing Insomnia Project

FUE WK 2 Improving Sleep and Managing Insomnia Project.

I’m working on a nursing report and need support to help me understand better.

Behavior Modification Project Part 4 – Final Report (50 points)At the end of the four-week journal period, write a final report consisting of a 3-4 page (750-1,000 words) discussion of the following questions. This report must be submitted in Microsoft Word doc or docx format and will be graded for detailed discussion of the required questions below as well as writing quality, grammar, and spelling.1. The new behavior: Describe, specifically, how your behavior has changed from the beginning of this project.2. New conditioned stimuli: In the beginning you were asked to identify objects or events you would associate with the new behavior to help it become established. Discuss how effective these stimuli become associated with the new behavior? Did any of these cues backfire on you? If so, why do you think they did not work? Did you adopt any other stimulus cues along the way to help make the behavioral change? 3. The reinforcements for the new behavior: How effective were the reinforcements and the reinforcement schedule that you chose? Did the type or schedule of reinforcement that you chose hinder your progress in any way? If so, how, and why do you think that was? Did other types of reinforcements occur to you that you might consider using in the future?4. Behavioral changes: Since making this change in your behavior, have you noticed other behaviors that have changed as well? Why do you think these additional changes occurred? Of these additional changes (if any) were you expecting these to occur? If so, why? Did any additional changes occur that you did not anticipate?5. Road Blocks: Did the obstacles you predicted occur? Did anything come up that you did not expect? How did you handle each of these issues?6. Results: To what degree was the change successful? Again, refer back to Parts 1 and 2 to review your reasons for the change and the goals you had. Plausible explanations for success or failure should be highlighted. If your plan failed, propose an alternative plan that might be more successful in the future. If your plan succeeded, discuss a brief plan to help you maintain the change.7. Personal Summary: Briefly discuss your reaction to this project. For example, were you surprised by the results that you found? Did anything along the way surprise you? Did you find this project useful? Why or why not?
FUE WK 2 Improving Sleep and Managing Insomnia Project

Essay Writing at Online Custom Essay

5.0 rating based on 10,001 ratings

Rated 4.9/5
10001 review

Review This Service




Rating: